Clinical trials: Physical activity
Autism Spectrum Disorder, Autism
Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children
The goal of this clinical study is to learn about the utility and performance of the EarliPoint(™) System: Evaluation for Autism Spectrum Disorder to monitor changes in a child's verbal ability, non-verbal learning, and social…
- Conditions
- Autism Spectrum Disorder, Autism, Developmental Delay, Autism, Early Infantile
- Trial name
- MEASURE-ASD1 (NCT05675371)
- Testing
- Assessment by Expert Clinician During Behavioral Intervention (ABA or similar), Assessment by the EarliPoint Assessment For Autism Spectrum Disorder
- Where
- 9 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- EarliTec Diagnostics, Inc
Advanced Solid Malignancies
A Phase I Open-label Study for Subjects With Advanced Malignancies
This is a first-in-human (FIH) Phase 1 dose escalation study to evaluate the safety, tolerability, PK, PD, and preliminary activity of PT01 administered IV in subjects with advanced malignancies.'
- Trial name
- PT01 (NCT04136834)
- Testing
- PT01 (Pegtomarginase)
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Athenex, Inc.
Advanced Solid Tumors
A Study of AP505 Injection in Patients With Advanced Malignant Solid Tumors
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of AP505 injection in patients with advanced solid tumors.
- Trial name
- NCT06723964
- Testing
- AP505
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- AP Biosciences Inc.
Plaque Psoriasis
Study of CRx-191 to Assess Activity in Plaque Psoriasis
CRx-191 is a proprietary synergistic combination drug candidate being evaluated by CombinatoRx for topical psoriasis therapy. CRx-191 was identified via a proprietary screening assay for novel drug combinations demonstrating…
- Trial name
- NCT00557739
- Testing
- mometasone furoate, nortriptyline HCl
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Zalicus
Inflammatory Bowel Diseases
Phase 1 Study for IPG11406 in Health Volunteer
A phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and food effect of orally administered IPG11406 in healthy adult…
- Trial name
- NCT06255834
- Testing
- IPG11406
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder
Opioid Use Disorders (OUD) cause significant burden to individuals, families, and the society. Our product - Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) - offers a cost-saving, home-based, user-friendly…
- Conditions
- Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Withdrawal Symptoms, Craving
- Trial name
- CBOT-OUD (NCT04850664)
- Testing
- CBOT + TAU
- Where
- 4 sites in United States
- Volunteers
- 190 people
- Sponsor
- Evon Medics LLC
Atopic Dermatitis
A Phase II Study in Adult Patients With Moderate to Severe Atopic Dermatitis
This proposed study is a randomized, double-blind, placebo-controlled, 3-arm parallel, multicenter phase II study, designed to explore the efficacy and safety of SHR0302 treatment for patients with moderate to severe atopic…
- Trial name
- NCT04162899
- Testing
- Drug: SHR0302
- Where
- 23 sites in China
- Volunteers
- 105 people
- Sponsor
- Reistone Biopharma Company Limited
Systemic Lupus Erythematosus
The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)
The purpose of this Proof of Concept (PoC) and Dose-finding (DF) basket study is to evaluate the efficacy and safety of orally administered Enpatoran over 24 weeks in systemic lupus erythematosus (SLE) and cutaneous lupus…
- Trial name
- NCT05162586
- Testing
- Enpatoran low dose, Enpatoran medium dose, Enpatoran high dose
- Where
- 153 sites in United States, Argentina and 20 more
- Volunteers
- 456 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer
A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancers, is a lethal disease with 3,221 new cases reported in 2021 in Korea.
- Conditions
- Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer, Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer
- Trial name
- NCT07687602
- Volunteers
- 69 people
- Sponsor
- AbbVie
Melanoma
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of melanomas.
- Trial name
- NCT03932253
- Testing
- FCN-159
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Gaucher Disease, Type 1
A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)
This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease Type 1.
- Trial name
- NCT00891202
- Testing
- Eliglustat tartrate
- Where
- 18 sites in United States, Bulgaria and 10 more
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Acute Myocardial Infarction (AMI), Asystole
SPIKE FLOW Endocardial Lead Safety and Performance Study
The objective of this study is to assess the safety and performance of the SPIKE FLOW endocardial lead. Primary objectives are to assess: safety in terms of freedom from Serious Adverse Events(SADEs); performance in terms of Mean…
- Conditions
- Acute Myocardial Infarction (AMI), Asystole, Bradycardia, AV Block
- Trial name
- SPIKE FLOW (NCT07820072)
- Testing
- Lead insertion, lead removal
- Where
- 3 sites in Italy
- Volunteers
- 131 people
- Sponsor
- FIAB SpA
Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression
First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- PAnTHA (NCT06217822)
- Testing
- 225Ac-PSMA-Trillium (BAY3563254)
- Where
- 35 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Ataxia Telangiectasia, Genetic Syndrome
Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study
Primary Objective To monitor and evaluate the long-term safety and tolerability of EDS-EP in AT patients. Secondary Objective To evaluate the long-term effect of EDS-EP on health-related Quality of Life (QoL; EQ-5D-5L scale).
- Trial name
- OLE-IEDAT (NCT03563053)
- Testing
- EryDex System
- Where
- 17 sites in United States, Australia and 9 more
- Volunteers
- 104 people
- Sponsor
- Quince Therapeutics S.p.A.
Rheumatoid Arthritis
A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
This multi-center observational study will evaluate the use and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT01670045
- Testing
- Tocilizumab
- Where
- 9 sites in Indonesia
- Volunteers
- 43 people
- Sponsor
- Hoffmann-La Roche
COPD
Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)
To evaluate changes in activity based on the use of portable oxygen concentrators combined with standard of care (SOC) long- term oxygen therapy versus SOC long-term oxygen therapy alone at 12 weeks in patients with COPD who…
- Trial name
- POC-STEP (NCT03513068)
- Testing
- Portable Oxygen Concentrator (POC)
- Where
- 11 sites in United States
- Volunteers
- 108 people
- Sponsor
- ResMed
Triple Negative Breast Neoplasms
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
The purpose of this study is to evaluate the safety, tolerability and clinical activity of pembrolizumab (MK-3475) in combination with six chemotherapy regimens as neoadjuvant treatment for participants with triple negative…
- Trial name
- NCT02622074
- Testing
- Pembrolizumab, Nab-paclitaxel, Anthracycline (doxorubicin)
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Metastatic Solid Malignancies
Consolidation Therapy in Patients With Metastatic Solid Malignancies
This study evaluates the effectiveness of Tumor Associated Peptide Antigens (TAPA) pulsed dendritic cell injections as a potential consolidation therapy for patients with metastatic solid malignancies (SM).
- Trial name
- NCT02705703
- Testing
- TAPA-pulsed DC vaccine
- Sponsor
- Kiromic BioPharma Inc.
IgA Nephropathy, Lupus Nephritis (LN)
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Clinical Activity of ADX-097 Administered Subcutaneously in Male and Female Participants Aged 16 Years or Older with Immunoglobulin A Nephropathy…
- Conditions
- IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
- Trial name
- NCT06419205
- Testing
- ADX-097
- Where
- 4 sites in United States, Brazil
- Volunteers
- 30 people
- Sponsor
- Akebia Therapeutics
Insulin Resistance
Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects
The objectives of this study are to evaluate the safety, tolerance and pharmacokinetics of HE3286 when administered daily for 28 days to obese adult subjects and to assess potential activity of HE3286 to decrease insulin…
- Trial name
- NCT00555451
- Testing
- HE3286
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Harbor Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.